Med-Fine Award | Portfolio Companies of Med-Fine Health Fund Ranked in Yaorongquan's '2025 Top 101 China Innovative Biopharma Companies List'
VelaVigo
Innovative Drug Developer
Lynk Pharmaceuticals
FIC/BIC Small Molecule Drug Developer
Artivila
Innovative Drug Developer
magAssist
Developer of Extracorporeal Artificial Heart Devices
August 2025, Suzhou, on the grand stage of the 2025 7th China Pharmaceutical Industry Expo (Pharma Expo), presented by the pharmaceutical information and precise networking platform ——PharmaCircleand CMC-CHINA China Pharmaceutical Industry ExpoThe authoritative list jointly initiated – "Top 101 China Pharmaceutical Industry 2025" and the 10 core industrial chain lists are grandly unveiled.
The TOP 101 List of China's Innovative Pharmaceutical Companies 2025 comprehensively evaluates companies based on market value, performance, R&D pipelines, commercialization, R&D investment, incubation, and BD, strictly selecting the pharmaceutical enterprises with the strongest innovation capabilities and development prospects. It objectively reflects the true landscape of the leading forces in China's innovative pharmaceuticals sector.
Among them,The invested companies of MiFang Health Fund have been ranked on the PharmaCircle "Top 101 List of China's Innovative Pharmaceutical Companies in 2025," which are:ImmVira, Allorion Therapeutics, Orange Sail Pharmaceuticals, Lingke Pharmaceutical。
The specific award-winning situation is as follows:
